Stockwinners Market Radar for December 14, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EST Axcella announces corporate restructuring, will reduce workforce by 85% - Axcella Therapeutics announced a repositioning of its strategy to focus on Long COVID and realize value from its platform and current programs. The company has initiated a process to explore a range of strategic alternatives to maximize shareholder value and is working with an investment bank to act as a strategic advisor for this process. As part of this repositioning, and to align with its current capital constraints, the company is announcing a series of organizational and program updates, including a reprioritization of its programs for Long COVID Fatigue and Nonalcoholic Steatohepatitis and a restructuring of operations to support its streamlined set of priorities. Axcella will reprioritize its efforts to focus on the significant unmet need and opportunity presented by Long COVID. Axcella's Phase 2a clinical trial results demonstrate the potential of AXA1125 to play an important role in treating patients suffering from Long COVID. Axcella's Phase 2a trial has been the only controlled trial to demonstrate statistically and clinically relevant improvement in fatigue in patients with Long COVID. Axcella is engaged in ongoing and productive reviews with regulators in the U.S. and Europe, and the company is aiming to advance its Long COVID Fatigue program into a potential registration trial. Axcella will be discontinuing its ongoing Phase 2b clinical trial of AXA1125 in NASH, while keeping the option to revisit this program should resource availability change. In September, Axcella reported positive data from a preplanned interim analysis from their trial of AXA1125 in NASH. At 24 weeks, there were statistically significant and clinically relevant improvements in the liver stiffness measurement (LSM) compared to placebo in the high dose arm for all subjects and statistically significant improvements in other non-invasive tests of liver fat and stiffness. Axcella's pre-clinical and clinical trial data for NASH demonstrated relevant activity and established a notable safety record for AXA1125, which the company applied to its clinical trial for Long COVID Fatigue. Axcella is realigning the organization to correspond to this shift in strategy and reprioritization of its programs, reducing its workforce by 85 percent, retaining certain employees to execute the strategic process. Among the departing employees are Bob Crane, Chief Financial Officer, and Virginia Dean, Chief People Officer. Axcella reached an agreement with SLR Investment Corp. to paydown the debt obligations of the previous agreement. With respect to the company's plans, no assurances can be made as to whether a strategic transaction will be recommended by the Board of Directors, and the Company does not intend to discuss developments with respect to the evaluation process unless a transaction is approved, or disclosure otherwise becomes appropriate.

19:07 EST First Hawaiian names James Moses CFO - First Hawaiian announced that it has appointed James M. Moses as Vice Chairman and Chief Financial Officer of First Hawaiian, Inc. and First Hawaiian Bank, effective January 3, 2023. "Jamie brings more than 20 years of diverse banking experience to the team. His track record of driving financial growth in complex organizations makes him a great fit for First Hawaiian. We look forward to integrating his expertise into our ongoing initiatives," said Bob Harrison, First Hawaiian, Inc. Chairman, President and CEO. "I want to thank Ralph Mesick for serving as our interim CFO and effectively guiding us through this transition period."

19:06 EST Falcon's Beyond to open new office in Manila in early 2023 - Falcon's Beyond announced plans to expand the company's footprint, internationally, with a new office scheduled to open in Metro Manila in early 2023. Falcon's Creative Philippines, Inc. is expected to employ approximately 20 new associates within the next quarter to support and expand Falcon's Creative Group, a division of Falcon's Beyond that provides master planning, creative design, media and audio production, attraction systems and experiential technology to customers around the world. The new office's team of local talent will include illustrators, architectural designers, modelers, and artists, as well as media and interactive gaming designers who will serve as an extension of the company's Orlando-based family of nearly 100 associates. "As someone of Filipino decent, it has been a lifelong dream of mine, as well as my father, to open a Falcon's office in the Philippines and support its vast array of local talent," said Cecil D. Magpuri, CEO of Falcon's Beyond. "We are excited to expand our company's footprint globally and build a team of passionate storytellers and creatives to support our portfolio of high-profile international entertainment projects."

18:37 EST Northern Trust raises prime rate to 7.5% from 7%, effective December 15

18:11 EST Kintara Therapeutics' treatment of DIPG receives FDA orphan designation - According to a post on the FDA's website, Kintara Therapeutics' treatment of Diffuse Intrinsic Pontine Glioma received orphan designation. Reference Link

18:06 EST AstraZeneca's anifrolumab receives FDA orphan designation - According to a post on the FDA's website, AstraZeneca's treatment of Idiopathic Inflammatory Myopathies, anifrolumab, received orphan designation. Reference Link

18:00 EST Lamb Weston raises quarterly dividend 14% to 28c per share - The Board of Directors of Lamb Weston Holdings approved a 14% annualized increase to the quarterly dividend. The Board declared a quarterly dividend of 28c per share of Lamb Weston common stock. "This increase is a clear demonstration of our capital allocation priority of returning cash to shareholders. This priority, along with investing in our business through capacity expansions and acquisitions to support long-term growth, and maintaining a strong balance sheet, consistently drive our capital allocation decisions," said President and Chief Executive Officer Tom Werner. The dividend is payable on March 3, 2023, to stockholders of record as of the close of business on Feb. 3, 2023.

17:35 EST Miromatrix Medical announces FDA clinical hold on miroliverELAP IND application - Miromatrix Medical announced that it was informed via e-mail from the FDA that the miroliverELAP Investigational New Drug, or IND, application for the treatment of acute liver failure has been placed on clinical hold. The miroliverELAP IND application was submitted in mid-November. The FDA indicated they will provide an official clinical hold letter to Miromatrix within 30 days. Miromatrix plans to provide additional updates pending communication with the FDA.

17:31 EST U.S. Bancorp raises prime lending rate to 7.5% from 7%, effective December 15

17:23 EST Boeing awarded $109.1M Missile Defense Agency contract modification - Boeing was awarded a $109.1M contract modification to a previously awarded, cost-plus-award-fee, cost-plus-incentive-fee contract. The value of this contact is increased from $5.06B to $5.17B. Under this modification, the contract period of performance is being extended by 12 months. This extension will allow completion of the Ground Test, or GT-08 test campaign; fielding of the Launch Management System software version 8D and Increment 6B.2 of the Missile Defense System; and installation of new Launch System Components and Launch Support Systems. The work will be performed in Huntsville, Alabama; Fort Greely, Alaska; and Vandenberg Space Force Base, California. The contract period of performance will be extended from December 2023 to December 2024. Fiscal 2023, 2024, and 2025, research, development, test and evaluations funds will be used on this effort; however, no funds are being obligated at this time. The Missile Defense Agency is the contracting activity.

17:20 EST Boeing awarded $255M Defense Logistics Agency contract modification - Boeing has been awarded a $255M modification exercising the five-year option period of a five-year base contract with one five-year option period for the F-15 depot program. This is a fixed-price-incentive and cost-plus-fixed-fee contract. The ordering period end date is May 17, 2027. Using military service is Air Force. Type of appropriation is fiscal 2022 through 2027 defense working capital funds. The contracting activity is the Defense Logistics Agency Aviation, Philadelphia, Pennsylvania.

17:09 EST Lennar says 'our balance sheet has never been in a stronger position' - Stuart Miller, Executive Chairman of Lennar, said, "We have also remained very focused on our balance sheet and liquidity. Accordingly, at year end, we had homebuilding debt to capital of 14.4%, the lowest in our history, no borrowings on our $2.6 billion revolver and cash of $4.6 billion. With liquidity of $7.2 billion and no debt maturing until fiscal 2024, our balance sheet has never been in a stronger position than it is today." Rick Beckwitt, Co-CEO and Co-President of Lennar, said, "Much of our balance sheet and inventory management progress was driven by our land strategy, while simultaneously driving sales, deliveries and managing production. During the quarter, we reassessed every deal in our land pipeline and worked with our strong land relationships to improve the underwriting on many deals. Our ending community count for the quarter was 1,208, which was up slightly from the third quarter. We also continued to make significant progress on our land light strategy. This was evidenced by our years supply of owned homesites improving to 2.5 years from 3.0 years and our controlled homesite percentage increasing to 63% from 59% year over year." Jon Jaffe, Co-CEO and Co-President of Lennar, said, "During the quarter, consistent with our strategy of cost control and cycle time reduction, our homebuilding machine continued to be intensely focused on carefully managing production. Our cycle time during the quarter was flat sequentially, indicating that the well documented supply chain and labor issues that impacted our productivity are beginning to become more manageable and perhaps subside. Our quarterly starts and sales pace were 3.6 homes and 3.7 homes per community, respectively, and we ended the fourth quarter with approximately 900 completed, unsold homes, less than one home per community, demonstrating our focus on inventory management."

17:05 EST Galmed announces eligibility for 180 day extension to meet Nasdaq requirements - Galmed announced that on December 13, it received a letter from Nasdaq, notifying the company that it is eligible for an additional 180 calendar day period, or until June 12, 2023, to regain compliance with the Nasdaq's minimum $1 bid price per share requirement.

17:04 EST Lennar sees FY23 deliveries 60,000-65,000

17:03 EST Lennar sees Q1 new orders 12,000-13,500 - Sees Q1 average sales price $440,000-$450,000; Gross margin % on home sales about 21.0%.

17:01 EST HSBC Bank USA raises prime lending rate to 7.5% from 7% - HSBC Bank USA, N.A., and its affiliates announced that they have raised their prime and reference rate to 7.50% from 7.00%, effective tomorrow.

17:00 EST FMC Corporation CTO Shelton to retire - FMC Corporation announced the planned retirement of Dr. Kathleen Shelton, executive vice president and chief technology officer, following a 33-year career in the chemical industry. Dr. Seva Rostovtsev, director of Discovery Chemistry, has been elected vice president and CTO by the board of directors. Shelton and Rostovtsev will transition responsibilities as part of the succession plan during the next several months until her retirement on March 31, 2023. Rostovtsev, who is a member of the R&D Leadership Team and currently reports to Shelton, will report to Mark Douglas, president and CEO, and will join the company's Operating Committee. "Innovation and the discovery of new technologies in support of society have been the hallmarks of Kathy's stellar career," said Douglas. "Those who have worked with her, however, know that she brings so much more to the table. She is passionate about research excellence and the development of new products that are more sustainable than today's offerings. Furthermore, she has never forgotten her early years as a chemistry educator, which inspired her throughout her corporate career to encourage students from all backgrounds to consider a profession in science, technology, engineering and math. On behalf of all of us at FMC, I thank her for her leadership and lasting contributions at our company. We wish her a happy, healthy and well-deserved retirement."

16:55 EST Sio Gene Therapies' board approves plan of liquidation and dissolution - Sio Gene Therapies' Board of Directors has determined that it is in the best interests of the company and its shareholders to dissolve the company and liquidate its assets, including its subsidiaries, and unanimously approved the dissolution and liquidation of the company, subject to shareholder approval. The company intends to call a special meeting of its shareholders in 1Q23 to seek approval of the Plan of Dissolution. If shareholders approve the plan, the company intends to file a certificate of dissolution, delist its shares of common stock from Nasdaq, satisfy or resolve its remaining liabilities and obligations, make reasonable provisions for unknown claims and liabilities, attempt to convert all of its remaining assets into cash or cash equivalents, and make distributions to its shareholders of remaining cash available for distribution. Upon the filing of the certificate of dissolution, the company intends to cease trading in its common stock, close its stock transfer books and discontinue recording transfers of shares of its capital stock. The company will establish a reserve, which will be used to pay all expenses and other liabilities and obligations, and will include reasonable provision for future expenses of liquidation and contingent and unknown liabilities. Based on this estimated reserve, the company will subsequently make liquidating distributions to shareholders as soon as practicable following the filing of the certificate of dissolution. The company will provide an estimate of such amounts in the proxy materials to be filed with the SEC.

16:44 EST Twitter shutting down newsletter platform Revue - Twitter's Martijn de Kuijper blogged earlier, in part: "From January 18 it will no longer be possible to access your Revue account. On that date, Revue will shut down and all data will be deleted...This has been a hard decision because we know Revue has a passionate user base, made up of people like you... We want to remind you that it is your responsibility to adhere to any applicable laws, rules and regulations in connection with your subscriber list and other data we share with you, and Twitter, Inc. has not obtained permission for you to use subscriber information for any purpose. We're grateful to everyone who has used our service over the years, and hope we can continue to help you build a community with your readers on Twitter." Reference Link

16:33 EST Ra Medical Systems regains compliance with NYSE American standards - Ra Medical Systems announces that it has received notification from the NYSE American LLC that the company has regained compliance with the NYSE American's continued listing standard. Specifically, the company has resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide.

16:32 EST Wells Fargo raises prime lending rate to 7.5% from 7% - Wells Fargo Bank, N.A., said it is increasing its prime rate to 7.5% from 7%, effective tomorrow, Dec. 15, 2022.

16:32 EST Goodyear Tire appoints Christina Zamarro as CFO - Goodyear Tire appointed Christina Zamarro to the role of EVP and CFO. Zamarro will succeed Darren Wells, who will become EVP and Chief Administrative Officer. Both appointments are effective Jan. 1, 2023. Zamarro joined Goodyear in 2007 after several years working for Ford Motor Company. She has more than 15 years with the company, culminating in her current role as VP, Finance and Treasurer. She also serves on Goodyear's Diversity & Inclusion Executive Council and on the board of L3Harris. Jordan Coughlin, previously Assistant Treasurer, Capital Markets, will become VP and Treasurer, also on Jan. 1. Goodyear's Investor Relations function will continue to be led by Christian Gadzinski, senior director, Investor Relations.

16:26 EST Greif announces 2030 sustainability targets - Greif announced new sustainability targets that build on the company's announcement in 2021 to reduce absolute Scope 1 and 2 greenhouse gas emissions 28% by the end of the decade. By 2030, Greif aims to: reach zero waste to landfill at 97% of its production facilities; make 100% of its products recyclable; achieve an average of 60% recycled raw material content across products; attain global gender pay parity by 2024; evaluate the sustainability performance for 80% of total spend with suppliers.

16:23 EST Centene announces new leadership appointments - Centene announced leadership changes and senior management appointments. Ken Fasola, currently EVP of Health Care Enterprises, will become President of Centene, continuing to report to Sarah London. Jim Murray, currently EVP, Chief Transformation Officer, will become EVP, COO, reporting to Fasola. Brent Layton will become Senior Advisor to the CEO, as he begins his transition towards retirement. Dave Thomas, currently EVP, Markets, will become CEO of Markets and Medicaid, reporting into Fasola. The appointments of Fasola, Murray, Layton and Thomas to their new roles are effective today. Additionally, the company appointed Alice Chen as Chief Health Officer, effective January 1, 2023, and Brian LeClaire as Chief Information Officer, effective December 5, 2022. Ken Fasola brings more than three decades of leadership in the healthcare industry, having most recently served as Centene's EVP of Health Care Enterprises and a member of the Office of the CEO. He joined Centene through the acquisition of Magellan Health where he served as CEO and board member. Jim Murray most recently served as Centene's Chief Transformation Officer. Previously, he was President and COO for Magellan Health. Brent Layton most recently served as President and COO for Centene, which he joined in 2006. Dave Thomas most recently served as Centene's EVP, Markets and was previously President and CEO of Fidelis Care. Prior to joining Centene, Chen was Chief Medical Officer at Covered California, the state's health insurance marketplace. She previously served as Deputy Secretary for Policy and Planning and Chief of Clinical Affairs for the California Health and Human Services Agency. Prior to joining Centene, Brian LeClaire was Director, Technology, for the healthcare team at Arsenal Capital Partners.

16:18 EST Plains All American to sell 21% interest in KFS facility for $270M - Plains All American, through its wholly owned subsidiary Plains Midstream Canada, announced that it has entered into definitive agreements to sell its 21% non-operated/undivided ownership interest in the Keyera Fort Saskatchewan, or KFS, facility to Keyera Corporation for approximately $270M. The transaction, which is subject to Canadian Competition Bureau review and closing conditions, is anticipated to close in the first quarter 2023. The divestiture includes all of Plains' interest in the Keyera Fort Saskatchewan facility. Under the agreement, Plains will maintain its current customers and contracts and lease back fractionation and storage capacity at the Keyera facility for a multi-year transition period, and the parties have agreed to improve the long-term propane, butane, condensate and C3+ connectivity between their respective assets.

16:16 EST Citi raises base lending rate to 7.5% from 7% - Citibank, N.A. said it has raised its base lending rate to 7.50% from 7.00%, effective tomorrow, Thursday, December 15, 2022.

16:15 EST Argan increases share buyback program to $125M from $100M - Argan announced that its Board of Directors approved an increase to the company's existing share repurchase program from $100M to $125M and declared a regular quarterly cash dividend in the amount of 25c per share of common stock, payable January 31, 2023 to stockholders of record at the close of business on January 20, 2023. "The expansion of our share repurchase program, along with our regularly quarterly dividend, reflects the Board's commitment to our disciplined capital allocation strategy and the confidence in our business," said David Watson, Argan's President and Chief Executive Officer. "Under the share repurchase authorization, we have repurchased approximately 14% of our outstanding shares at a cost of approximately $84 million since November 2021. As our subsidiaries continue to contribute to the growth in backlog, currently exceeding $0.8 billion, and to successfully execute on their work, we believe the future for Argan is substantial."

16:12 EST Aligos Therapeutics initiates dosing in ALG-125755 trial - Aligos Therapeutics reported that dosing with ALG-125755, a small interfering RNA targeting the production of hepatitis B surface antigen, or HBsAg, was initiated in subjects with chronic hepatitis B, or CHB, in Study ALG-125755-501.

16:10 EST Longview Acquisition II to redeem public shares before year-end - On December 14, Longview Acquisition Corp. II stockholders approved an amendment to Longview's Amended and Restated Certificate of Incorporation and and an amendment to Longview's Investment Trust Management Agreement by and between the company and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as trustee to allow Longview to change the date by which the company must consummate a business combination from March 23, 2023 to September 23, 2023 or such earlier date as is determined by the company's board of directors in its sole discretion and publicly announced by the company and change the date on which Continental must commence liquidation of the trust account from the earlier of the company's completion of an initial business combination and March 23, 2023 to the earliest of the company's completion of an initial business combination, September 23, 2023 or such earlier date as is determined by the Board in its sole discretion and publicly announced by the company. Following the implementation, the Board set December 14 as the date by which the company must consummate a business combination. The company expects to redeem all of its outstanding Class A common stock on or prior to December 29.

16:08 EST Associated Banc-Corp raises prime rate to 7.5% from 7%, effective December 14

16:06 EST Vigil Neuroscienc:1st patient dosed in trial studying VGL101 in ALSP patients - Vigil Neuroscience announced that the Company dosed its first patient in the Phase 2, proof-of-concept clinical trial evaluating VGL101, a fully human monoclonal antibody TREM2 agonist, in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia ALSP. "Dosing the first ALSP patient in the IGNITE Phase 2 trial represents a significant clinical milestone for Vigil and for people living with this rare, rapidly progressing, fatal disease with a significant unmet need," said Ivana Magovcevic-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "This is also an important first step in reaching our anticipated milestone of establishing proof of concept in ALSP in 2023 and evaluating the therapeutic potential of VGL101 in patients for whom there are currently no approved treatments." "Interim topline data from our Phase 1 trial in healthy volunteers demonstrated that VGL101 is safe, well tolerated, brain penetrant, and produced robust and durable reductions in sTREM2, validating its mechanism of action. Now, we look forward to evaluating the safety and tolerability of VGL101 as well as its effects on imaging and biomarkers of disease progression in this first ever interventional trial for people living with ALSP," said Spyros Papapetropoulos, M.D., Ph.D., Chief Medical Officer of Vigil.

16:03 EST Personalis CEO West to retire - Personalis announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the company of his decision to retire as CEO and a director at the end of the calendar year. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. West will continue to serve as an advisor to the Board. "We thank John for his vision and dedication for more than a decade and wish him the best in the future," said Karin Eastham, Personalis Board Chair. "The Board will immediately initiate a search for a successor. Under the leadership of Mr. Tachibana and Mr. Hall, we are committed to our strategy, particularly focused on the development of our NeXT Personal(R) MRD platform. We are fortunate to have an experienced and highly capable senior management team to continue leading the company and working closely with Aaron and Chris. I look forward to working with the leadership team as we recruit a new Chief Executive Officer."

16:00 EST Champions Oncology trading resumes

15:56 EST Champions Oncology trading halted, volatility trading pause

15:09 EST Gorilla Technology Group Inc trading resumes

14:36 EST Motorola Solutions acquires Rave Mobile Safety - Motorola Solutions announced it has acquired Rave Mobile Safety, "a leader in mass notification and incident management that helps organizations and public safety agencies communicate and collaborate during emergencies," the company said. "State and local governments and enterprises, including hospitals, rely on Rave's cloud-native, customizable platform to support emergency coordination. Users can effectively communicate operational updates and alerts, such as health emergencies, lockdowns and evacuations, so people are better informed to take appropriate action. The platform is also used by thousands of K-12 schools and higher education institutions across the U.S. Rave's panic button solution can immediately provide real-time incident details and essential data like location to 9-1-1 call takers and first responders, and its incident management solution helps to coordinate the emergency response across school safety personnel, administrators and first responders," it added. The Rave platform will be integrated into Motorola Solutions' technology portfolio, which includes access control, video security, body-worn cameras, critical communications, command center software and weapons detection solutions. Terms of the transaction were not disclosed.

14:12 EST China Jo-Jo Drugstore trading resumes

14:07 EST China Jo-Jo Drugstore trading halted, volatility trading pause

13:41 EST SoFi Technologies spikes over 8% after CEO Noto buys $5M in shares - SoFi Technologies is trading up over 8% or 37c per share on Wednesday, to $4.80, after the company CEO, Anthony Noto, disclosed that he had had purchased over $5M in company shares.

12:41 EST Amazon Ads providing U.S. advertisers free access to Shutterstock library - Amazon (AMZN) stated in a blog post: "To help Amazon Ads marketers drive performance and enhance their brand presence, Amazon Ads and Shutterstock are now providing advertisers in the US with free and easy access to Shutterstock's library of more than 390 million high-quality licensed assets. Advertisers can access the images directly within the Amazon Ads console using the creative assets application to search and browse for creative that meets their brand's needs... Both vendors and sellers who are registered for advertising will have free access to Shutterstock's collection of high-quality licensed photographs that can be used across placements in Sponsored Display and Stores." Reference Link

12:00 EST United States Natural Gas Fund falls -7.3% - United States Natural Gas Fund is down -7.3%, or -$1.55 to $19.72.

12:00 EST Petrobras falls -10.8% - Petrobras is down -10.8%, or -$1.09 to $9.04.

12:00 EST Mistras rises 15.4% - Mistras is up 15.4%, or 66c to $4.94.

11:50 EST JOFF Fintech Acquisition to unwind before year-end - On December 14, the stockholders of JOFF Fintech Acquisition Corp. approved an amendment to the company's amended and restated certificate of incorporation to allow the company to unwind and redeem all of its outstanding public shares on the later of December 14 or the date of effectiveness of the charter amendment and to implement an amendment to the company's trust agreement with Continental Stock Transfer and Trust Company so as to permit the company to withdraw from its trust account certain additional amounts of interest income to provide the company with a 60% share of the cash tax savings resulting from the early liquidation. As of the close of business on December 14, the public shares of Class A common stock will be deemed cancelled and will represent only the right to receive the redemption amount. There will be no redemption rights or liquidating distributions with respect to the redeemable warrants, which will expire worthless upon the liquidation of the company, JOFF Fintech Acquisition announced.

11:36 EST German Ministry of Defense to procure 35 F-35 Lightning II aircraft - The German Ministry of Defense announced it is procuring 35 Lockheed Martin 5th Generation F-35 Lightning II aircraft. The agreement includes a comprehensive package of engines, role-specific mission equipment, spare and replacement parts, technical and logistic support, training and armament.

10:52 EST Delta Air Lines: December business 'off trend,' sees improvement in January

10:42 EST Delta sees $30B of travel spending in 2023

10:41 EST Delta sees January revenue 'significantly' better than December - Comments taken from Delta's Financial Outlook & Strategic Update conference call.

10:34 EST Visa to invest $1B in Africa over next five years - During the U.S-Africa Business Forum, Visa announced a pledge to invest $1B in Africa over the next five years to advance resilient, innovative, and inclusive economies across the continent. Visa's expanded investments demonstrate the company's long-term commitment to Africa's growth potential and will help enable greater access to digital payments as an entry point for expanding formal financial services for individuals and merchants. The pledge will further scale Visa's operations in Africa, and deepen collaboration with strategic partners including governments, financial institutions, mobile network operators, fintechs and merchants. The investments will also focus on strengthening the payment ecosystem through new innovations and technologies, supporting digitization of economies, and investing in upskilling, talent development and capacity building. In line with Visa's corporate purpose to be the best way to pay and be paid, these investments will facilitate additional opportunities to expand financial inclusion. Visa is dedicated to empowering small- and women-led entrepreneurship in Africa through its operations and community programs.

10:29 EST AIG Financial Products Corp. files for Chapter 11 bankruptcy - In a regulatory filing, AIG said, "On December 14, 2022, American International Group announced that a wholly-owned subsidiary called AIG Financial Products Corp. filed a voluntary petition to reorganize under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware and filed a proposed plan of reorganization. The reorganization will not have a material impact on the consolidated balance sheets of AIG or Corebridge Financial, Inc. or their respective businesses, and concludes AIG's wind-down of FP, a process that has been ongoing since the 2008 financial crisis. An independent Special Committee of FP's board of directors determined that the Filing and Plan of Reorganization present the best path forward to conclude the wind-down of FP. Alvarez & Marsal North America, LLC and Latham & Watkins LLP are advisors to FP. FP, formerly based in Connecticut, has no material operations or businesses and no employees. FP's subsidiaries are not a party to the Filing and will continue to manage any remaining positions with a very limited number of counterparties. As disclosed in the Filing, AIG is FP's largest remaining creditor. In 2008, AIG received emergency loans from the U.S. Federal Reserve to ensure the stability of the financial system. AIG then extended a substantial portion of the 2008 Bailout Funds to FP in the form of inter-company loans to satisfy FP's obligations to counterparties through and following the Financial Crisis. As of January 2013, AIG fully repaid the 2008 Bailout Funds to the U.S. Federal Reserve. From an accounting perspective, although there are still significant amounts due from FP to AIG through inter-company loans, the Filing will have no net impact on AIG's consolidated financial statements. Additionally, all of AIG's and FP's Financial Crisis losses were recognized in AIG's financial statements in 2008. Since 2008, FP has been subject to various lawsuits related to the Financial Crisis, with only one such lawsuit still pending in a Connecticut state court. All other lawsuits have been resolved. The Connecticut Litigation was brought in late 2019 by 46 former Connecticut-based FP executives who are seeking to recover profit-sharing bonuses they allege they are entitled to under legacy deferred compensation plans that pre-date the Financial Crisis. The plaintiffs allege that the profit-sharing bonuses are recoverable despite the fact that FP's tens of billions of dollars in Financial Crisis losses led to the need for the 2008 Bailout Funds. These Financial Crisis losses eliminated all of the profit-sharing bonus account balances. The claims in the Connecticut Litigation are fundamentally identical to those brought in 2014 in an English trial court by former London-based executives of FP and related FP entities and funded by an affiliate of Therium Capital Management Limited, a litigation finance firm. In 2018, the English trial court found in favor of the plaintiffs; however, in 2020, a unanimous English Court of Appeal, applying Connecticut law, reversed the trial court decision and ruled in favor of FP, holding that the former executives were not entitled to any of the claimed profit-sharing bonus amounts as a matter of law. The Supreme Court of the United Kingdom denied leave to appeal from the Court of Appeal's decision, making the Court of Appeal's decision final and binding. FP has contended in the Connecticut Litigation, as it did in the English Litigation, that under the terms of the deferred compensation plans, former FP executives are not entitled to any recoveries because FP never generated profits following its tens of billions of dollars in Financial Crisis losses. Furthermore, the terms of the deferred compensation plans provide that upon a bankruptcy filing by FP, any financial obligation of FP under the deferred compensation plans is subordinate to all other liabilities of FP. Pursuant to the terms of the Plan of Reorganization, the only funds available to the 46 former FP executives to extinguish their claims would be an equal share in a limited pool of $1 million."

10:00 EST Adecoagro falls -6.6% - Adecoagro is down -6.6%, or -50c to $7.12.

10:00 EST Paysafe falls -8.5% - Paysafe is down -8.5%, or -$1.15 to $12.36.

10:00 EST Mistras rises 11.9% - Mistras is up 11.9%, or 51c to $4.79.

09:53 EST Charter sinks after detailing spending plans to update network - Charter Communications said last night in its investor meeting slides that its targets to spend $5.5B in capital expenditures for a network evolution footprint. The $5.5B will be partly offset by capital expenditure and operating expense efficiencies as a result of network evolution, Charter noted. The company plans on expanding plant capacity from 750/860 MHz to 1.2 GHz, with 1.8 GHz DOCSIS 4.0 capable equipment in whole markets across much of its footprint. The network evolution should be essentially complete by the end of 2025, according to Charter. The company currently expects full year 2023 capital expenditures, excluding line extensions capital expenditures, to be between $6.5B and $6.8B. Charter currently expects capital expenditures, excluding line extensions capital expenditures, to peak in either 2024or 2025 due to network evolution, and to decline thereafter. Shares of Charter are down 14% to $338.76 in morning trading.

09:47 EST ABM falls -6.6% - ABM is down -6.6%, or -$3.00 to $42.61.

09:47 EST Studio City rises 10.8% - Studio City is up 10.8%, or 61c to $6.24.

09:47 EST Rev Group rises 13.7% - Rev Group is up 13.7%, or $1.82 to $15.10.

09:35 EST Theseus Pharmaceuticals Inc trading resumes

09:30 EST Corner Growth Acquisition Corp 2 trading halted, volatility trading pause

09:22 EST Mill City enters $5M short-term loan with Mustang Litigation Funding - Mill City Ventures III announced that, in accordance with its previously announced letter of intent regarding a proposed merger transaction with Mustang Funding, LLC dba Mustang Litigation Funding, it has entered into a $5 million short-term financing arrangement with Mustang in furtherance of the proposed merger. The related short-term note is scheduled to mature on the ninth-month anniversary of the loan.

09:20 EST Jeffs' Brands enters non-binding LOI to acquire 50% of SciSparc subsidiary - Jeffs' Brands (JFBR) entered into a non-binding letter of intent with SciSparc (SPRC) for the purchase of 50% of SciSparc's wholly owned subsidiary, SciSparc Nutraceuticals, for approximately $3M in cash or a combination of cash and ordinary shares of the Company, as agreed by the parties in the definitive agreement. The Brand is profitable with millions of dollars in annual sales. The acquisition is subject to, the negotiation and the execution of a binding definitive agreement. There can be no assurances that the acquisition will proceed, nor can there be any assurance as to the final definitive terms thereof, including the final purchase price or composition thereof.The Brand sells hemp-based, top-ranked products, including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. The Brand offers eight variations of natural hemp candy supplements under two parent Amazon Standard Identification Number on Amazon that are differentiated by their hemp oil potency. Oz Adler, the Chairman and a director of the Company is the CEO and CFO of SciSparc and the Chairman of SciSparc.

09:17 EST SciSparc enters non-binding LOI to sell 50% interest in subsidiary for $3M - SciSparc (SPRC) entered into a non-binding letter of intent for the sale of a 50% interest in its wholly owned subsidiary, SciSparc Nutraceuticals, to Jeffs' Brands (JFBR), for $3M in cash or a combination of cash and ordinary shares of Jeffs' Brands, as agreed by the parties. The sale is subject to the negotiation and the execution of a binding definitive agreement. There can be no assurances that the sale will proceed, nor can there be any assurance as to the final definitive terms thereof, including form of consideration. Recently, the Company entered into a non-binder letter of intent with Jeffs' Brands to establish a joint venture together for the development of a new food supplements product line and the online marketing of such supplements. Oz Adler, CEO and the CFO of the Company, is the Chairman of Jeffs' Brands and the Chairman of the Company is a director of Jeffs' Brands.

09:11 EST AirSculpt features former Real Housewives as latest AirSculpt clients - AirSculpt Technologies and its Founder and CEO, Dr. Aaron Rollins join former Real Housewives stars Vicki Gunvalson and LeeAnne Locken to reveal their AirSculpt results on Instagram Live on December 15. "We're excited to share Vicki and LeeAnne's amazing AirSculpt results," said Stephanie Greene, Chief Marketing Officer of AirSculpt Technologies. "They are both beautiful women, inside and out, and their transformative results from AirSculpt not only enhance their beauty but dare I say, unlock even more of the trademark confidence and moxie of two of our favorite Housewives." AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at Elite Body Sculpture offices.

09:11 EST SKYX Platforms to initiate pre-sales campaign for Smart SkyPlug - SKYX Platforms Corp. announced that it will initiate pre-sales of its Smart SkyPlug product for safe and fast installation of light fixtures and ceiling fans on Monday December 19, 2022.

09:09 EST Kins Technology Group approves extension for consummation of combination - KINS Technology Group announced that its stockholders have approved an extension of the date by which the Company must consummate a business combination from December 16, 2022 to June 15, 2023 at the special meeting of stockholders held on December 9, 2022. The Extension provides KINS with additional time to complete the previously announced proposed business combination with CXApp Holding Corp. KINS Capital LLC, the sponsor, will contribute to the Company as a loan $0.04 for each share of Class A Common Stock that is not redeemed in connection with the stockholder vote to approve the Extension for each month until the earlier of the date of the stockholder meeting held in connection with the stockholder vote to approve the Business Combination, or the date that $225,000 has been loaned. The Company previously extended the period of time it has to consummate its initial business combination from June 17, 2022 to December 16, 2022. On September 25, 2022, KINS entered into a definitive business combination agreement pursuant to which it would acquire CXApp and its workplace experience app platform and technologies, indoor mapping, events platform, augmented reality and related business solutions in exchange for 6.9 million shares of KINS capital stock valued at $69 million. Upon the closing of the Business Combination, which is expected in early first quarter of 2023, the combined company will be re-named CXApp Inc. and plans to list on Nasdaq, under the new ticker symbol, "CXAI."

09:05 EST Virpax Pharmaceuticals receives PIND application guidance from FDA for NobrXiol - Virpax Pharmaceuticals announced that it has received pre-investigational new drug, or PIND, application guidance from the FDA for NobrXiol, the company's product candidate for the delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utilizes the Nanomerics Molecular Envelope Technology, or MET, as its delivery system to cross the blood brain barrier, propelling the cannabidiol nanoparticles through the nose to the brain via the olfactory nerve. The main purpose of a pre-IND submission is to obtain FDA guidance on the overall development plan for a new drug and to identify any need for further data prior to submitting the IND.

09:04 EST Movano reports preliminary results of pivotal hypoxia trial with its smart ring - Movano Health announces successful preliminary results of its pivotal hypoxia trial, which was completed in conjunction with the University of California, San Francisco, or UCSF, to assess the accuracy of its smart ring's blood oxygen saturation, or SpO2, and heart rate data. In comparing the overall accuracy of the ring's data with data from the study's reference devices, Movano Health's ring resulted in an approximate 2% margin of error, well below the FDA consensus standard of 4% for SpO2. Additionally, the Company's device measured heart rate that had root mean square error of approximately 2 BPM, which is also in line with the FDA's requirements. Given these positive results, Movano Health expects to file for FDA clearance of these metrics in 2023. Following a successful pilot study in July 2022, the latest study used the same protocol required by the FDA for the submission and involved 11 subjects of mixed genders and ethnicities.

09:03 EST Shyft Group appoints Dunn as President, Fleet Vehicles, Services - The Shyft Group named industry veteran John Dunn as President, Fleet Vehicles and Services (FVS), effective in January 2023. In his new role, Dunn will be responsible for all aspects of the business, working with his senior leadership team to guide the strategic vision of the business unit and overseeing its implementation. Dunn brings extensive experience in manufacturing growth, operational improvement, customer relations, and full product development, having most recently served as the President and CEO, North and South America of Plastic Omnium, Clean Energy Systems.

09:02 EST Muscle Maker's Pokemoto signs first agreement in California - Pokemoto announced it has signed its first franchise agreement in Northern California. This franchise agreement marks the brand's entrance into the West Coast and the state of California bringing the brand's market count to 16 states once opened. The recently announced milestone of 50 franchise agreements signed highlighted the company's expansion into 16 new and existing markets which include, among others, Florida, Kansas, New York, New Jersey, Connecticut, Pennsylvania, Massachusetts and now California. The franchise agreement in Northern California will focus on Sonoma and Marin counties. The franchise group benefitted from Pokemoto's Veteran discount program. The program offers a $15k discount on the initial $25k franchise fee bringing the total cost per agreement to $10k and is in place as a thank you to the men and women who have served in the United States military. The program includes active and retired members of all branches of the United States military. The CEO of Pokemoto, Michael Roper stated "Entering a new market is always a big win for the company. We're in growth mode and want to plant as many flags as possible as a brand. Now we get to introduce Pokemoto in Northern California and can tout that we have a coast-to-coast presence. Just two weeks ago we announced reaching our milestone goal of 50 franchise agreements signed by the end of the year and we're still signing deals with a couple weeks left in the year. We'll continue to execute against our franchising strategy while leveraging our partnerships which help us connect with entrepreneurs looking for a unique opportunity in the restaurant space and believe we'll continue to see our efforts bear fruit in 2023."

09:02 EST Inspira Technologies signs agreement with Sheba Medical Center - InspiraTechnologies announced that it has signed an agreement to conduct a clinical study of the HYLA blood sensor with Sheba Medical Center in Israel. The clinical study, expected to commence in the first quarter of 2023, will be performed in an operating room setting in patients undergoing open heart surgery using a cardiopulmonary bypass machine, or CPB. The study objective is to further evaluate the HYLA blood sensor's capabilities to measure blood gases in a non-invasive and continuous manner. The study results are expected to have a significant contribution to the product's development. Sheba Medical Center is internationally known for its groundbreaking medical research, integrating basic research, translational research and clinical studies across a broad spectrum of medical disciplines.

08:38 EST NLS Pharmaceutics closes initial tranche of $10M purchase agreement - NLS Pharmaceutics announced the closing of its previously publicized purchase agreement with BVF Partners comprised of an initial closing of $10M in exchange for 11,494,253 common shares, representing a purchase price per share of $0.87. As part of the financing, in a second potential closing, BVF will have the right, following a successful end of phase 2 meeting with the U.S. Food and Drug Administration, among other closing conditions, to purchase units at a per unit purchase price of $1.50, which units will consist of common shares, as well as a common share warrant to purchase up to one and a half common shares at an exercise price of $2.03 per share. If this option is exercised in full, BVF will receive 20 million common shares plus common share warrants to purchase 20 million NLS common shares at $2.03 per share. Laidlaw & Company Ltd. acted as exclusive introducing broker for the offering. NLS intends to use the net proceeds from the offering to accelerate the ongoing clinical development of its lead product, Mazindol ER for the treatment of narcolepsy, to advance NLS-4 and other product candidates, to support business development and licensing activities, and for general corporate purposes. With this financing, NLS expects to be able to fund its operations through 2025, beyond the anticipated submission of its New Drug Application for Mazindol ER in narcolepsy, expected in late 2024 or early 2025.

08:35 EST HUMBL announces $20M equity financing agreement - HUMBL announced HUMBL and GHS Investments, LLC have entered into an Equity Financing Agreement in which GHS Investments has agreed to purchase up to $20,000,000 of HUMBL common stock. The right to cause GHS Investments to purchase these shares is solely at HUMBL's election.Pursuant to the Equity Financing Agreement, GHS Investments agreed to purchase up to $20,000,000 of HUMBL common stock following the receipt of put notices from HUMBL and subject to certain conditions. If HUMBL elects to cause GHS Investments to purchase shares, the shares will be purchased at a 20% discount to the average of the three lowest closing prices of HUMBL's common stock in the prior 10 trading days. Following an uplist to Nasdaq or an equivalent national exchange, the conversion discount would drop from 20% to 10%. HUMBL will have the right to cause GHS Investments to purchase shares under the agreement following the effectiveness of an S-1 Registration Statement. HUMBL may choose the dollar amount of each put notice delivered to GHS Investments; provided, however, the maximum dollar amount of any put cannot exceed the lesser of 200% of HUMBL's average daily trading volume in the previous 10 trading days and $500,000.

08:34 EST Dyadic International announces study published on its DYAI-100 COVID-19 - Dyadic International announced that its study titled "Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel 85 Protects K18-hACE2 Mice against Lethal Virus Challenge" has been published in VACCINES, a leading peer-reviewed scientific journal as part of the Special Issue "Vaccine Candidate against SARS-CoV-2". Conducted together with leading scientists from several other organizations, this study exemplifies Dyadic's focus building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health. "Many of the newly evolving pathogens are zoonotic viruses and they are contributing to a global threat. Safe and effective vaccines that can be developed rapidly and economically manufactured in global quantities following an outbreak are required to effectively combat these diseases. The efficacy, protection and safety data reported from this study further supports the expansive library of data - demonstrating a novel approach for the C1-cell protein production platform to be broadly applied for rapid development and manufacturing of vaccines and antibodies for both human and animals," said Dr. Ronen Tchelet, Dyadic's Chief Scientific Officer.

08:32 EST Processa Pharmaceuticals announces results from Phase 2A study of PCS12852 - Processa Pharmaceuticals announced positive top-line results on the clinical symptoms associated with gastroparesis from a 4-week Phase 2A study of PCS12852, which is being developed for the treatment of patients with gastroparesis. The trial was a placebo-controlled, randomized, dose-response study designed to evaluate the safety, efficacy, and pharmacokinetics of two dosage regimens of PCS12852 vs placebo. Processa previously announced an improvement in the primary endpoint of the study, the gastric emptying rate, in patients that received a 0.5 mg daily dose of PCS12852. The results from this Phase 2A study also showed that clinically meaningful improvements in gastroparesis symptoms occurred in more patients receiving the PCS12852 0.5 mg daily dose than the placebo daily dose. The study included 25 patients with moderate to severe gastroparesis that received a daily dose of PCS12852 or a placebo. Three patients dropped out of the study. Two patients were in the 0.5 mg group and one in the 0.1 mg group. Although the study was not powered to show a statistically significant difference from the placebo, 100% of the patients receiving the 0.5 mg daily dose of PCS12852 and no rescue medication from Day 22-28 had a clinically meaningful reduction in the total ANMS GCSI-DD score while only 57% of the placebo group had a clinically meaningful reduction. In addition, the magnitude of the improvement for the total ANNMS GCSI-DD score and for the subscores was greater for the 0.5 mg PCS12852 group than the placebo group. The 0.1 mg PCS12852 daily dose group showed little to no improvement in gastroparesis symptoms. "This Phase 2A gastroparesis study shows a trend toward an increase in the gastric emptying rate and clinically meaningful improvements in gastroparesis symptoms in patients receiving a 0.5 mg daily dose of PCS12852," said Dr. Sian Bigora, Chief Development Officer at Processa. "The reduction in clinical symptoms and the continued improvement in the total ANMS GCSI-DD score and multiple individual symptom scores were better for the PCS12852 0.5 mg daily dose group than placebo or the 0.1 mg group. These findings suggest that a longer treatment than 28 days may result in greater differences in the gastroparesis symptoms for the 0.5 mg PCS12852 daily dose group when compared to the placebo dose group. These results, consistent with the previous pre-clinical and clinical studies, give us confidence that dosing 0.5 mg of PCS12852 daily for at least 12 weeks should improve the clinical symptom score more than a placebo treatment." PCS12852 was shown to be generally well-tolerated, with most AEs occurring in the 0.5 mg dose group and consisting of either a mild or moderate grade.

08:28 EST Delta Air Lines sees FY22 CapEx 5.8B; FY23 CapEx $5.5B; FY24 CapEx $5B - Sees adjusted net debt: FY22: $22B; FY23: $19B-$20B; FY24: $15B. Sees 2023 total fleet count 1,294 vs. 1,269 in 2022.

08:27 EST Smith-Midland Corp CFO AJ Krick to depart, Stephanie Poe to succeed - Smith-Midland Corporation announced that Stephanie Poe, the Company's current Controller, has been promoted to the Company's CFO effective January 1, 2023. AJ Krick, who has served as the Company's CFO since 2018, is leaving the Company to start his own CPA business, and will serve in a consulting capacity with the Company to help ensure a smooth transition.

08:24 EST Brandywine Realty announces tender offer for guaranteed notes - Brandywine Realty Trust announced that its operating partnership, Brandywine Operating Partnership, L.P., has commenced a cash tender offer for any and all of the $350,000,000 outstanding principal amount of its 3.95% Guaranteed Notes due February 15, 2023. The Tender Offer consists of an offer on the terms and conditions set forth in the offer to purchase, dated December 14, 2022, and the related letter of transmittal and notice of guaranteed delivery to purchase for cash any and all of the Notes.The Tender Offer will expire at 5:00 p.m., New York City time, on December 20, 2022, unless extended or earlier terminated. Holders of Notes must validly tender and not validly withdraw their Notes prior to or at the Expiration Date to be eligible to receive the Purchase Price.

08:23 EST PaxMedica launches updated corporate website - PaxMedica announced that the Company has launched a newly updated corporate website. Howard Weisman, Chief Executive Officer of PaxMedica, commented, "Our new website underscores our ongoing commitment to develop therapeutic advancements to treat core symptoms of autism and other potentially related disorders with intractable neurologic symptoms. The refreshed site represents the first step in providing a more robust platform for sharing information with our stakeholders, including families and investors, who are interested in our research."

08:20 EST Mersana Therapeutics announces E.C. designated UpRi Orphan Medicinal product - Mersana Therapeutics announced that the European Commission, E.C., has designated upifitamab rilsodotin, UpRi, as an orphan medicinal product for the treatment of ovarian cancer. UpRi is Mersana's first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that is designed to enable a high drug-to-antibody ratio and controlled bystander effect. "Receiving this orphan designation in the European Union is an important regulatory milestone for Mersana as we seek to expedite UpRi's global development," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "This designation reinforces the unmet needs that patients with ovarian cancer continue to face today. We look forward to advancing our ongoing clinical trials, which aim to establish UpRi as a foundational medicine in ovarian cancer."

08:19 EST Arqit Quantum announces change in technology strategy - Arqit Quantum announces a significant change in its technology strategy, resulting from innovation which is expected to have a positive impact on the company's future financial position and results. Arqit's technology involves the supply of a lightweight software agent to end point customer devices or cloud machines for the purpose of making encryption keys which are zero trust and computationally secure. As announced by Arqit in May 2022, the proof of this capability was independently assured by the University of Surrey, a GCHQ Accredited Centre of Excellence for Cyber Security, and PA Consulting. As part of the background technology which allows Arqit's software agent to operate, identical sets of random numbers must be delivered securely and frequently to data centres. Arqit invented a quantum satellite protocol to facilitate delivery of replicated entropy, which it believes is unique in achieving delivery with quantum safety. Pending the launch of its satellites, Arqit has been using a terrestrial method of delivering replicated entropy using a set of classical digital hardware and software elements, and following further innovation this year, has recently deployed an advanced version of terrestrial delivery. The security of end point encryption keys is as strong with the terrestrial method as it is with the satellite method. Arqit has therefore concluded that it no longer needs to incorporate satellites or the associated ground infrastructure into its core QuantumCloud offering in order to deliver a quantum safe product. There is continued demand for quantum satellite delivery of replicated entropy from customers with ultra-secure use requirements, such as government defence departments. To these customers the satellite method offers advantages in sovereign, on-premises control of key agreement and in eavesdropper detection. Arqit believes that other attempts to generate security through quantum satellite transmission are flawed, and in its invention of a new set of protocols, it solved those problems. Because the security of Arqit's quantum satellite technology cannot be deduced from individual patent filings, all the patents, code, protocols and proprietary IP have been independently validated by an eminent professor in this domain with a leading UK university and the conclusions shared under NDA with potential buyers. Arqit intends to sell its quantum satellite currently under construction to a customer with such ultra-secure requirements. Following the sale of its satellite currently under construction, Arqit will build no further satellite infrastructure and intends to licence its quantum satellite IP to subsequent customers with similar requirements, which will enable those customers to build their own systems. Arqit is currently in discussions with a number of potential customers regarding both the purchase of its existing satellite and the licence of its quantum satellite IP. Arqit expects the licencing of its quantum satellite IP to generate additional revenues without additional capital expenditure. Arqit expects that these changes to its technology strategy will result in a positive effect on its future results, with a portion of capitalised satellite costs recouped through the planned sale of the satellite currently under construction, additional revenues through the licencing of its quantum satellite IP and the elimination of future capital and operating expenditures associated with use of satellites as part of its core product offering. Arqit intends to continue to perform under its satellite construction contract with the European Space Agency and recognise the related project revenues generated thereunder.

08:17 EST BioSig Technologies PURE EP featured in abstract presentation - BioSig Technologies announcedthat its PURE EP System was featured in an abstract presentation during the 15th Asia Pacific Heart Rhythm Society, APHRS, Scientific Session in Singapore. Results from the randomized study reveal the PURE EP System's potential to promote shorter procedural times and higher cost savings during catheter ablations. The study enrolled 29 patients with non-paroxysmal AF with post-ablation arrhythmia recurrence. The primary objective was to determine the difference in procedural times when comparing ablations guided by PURE EP's electrocardiogram visualization to the conventional ECG recording system. Study results demonstrated that the PURE EP System led to a mean procedure time reduction of 11.3 minutes. Given that the mean cost of operating room time is approximately $37 per minute1, the procedural time savings demonstrated by the PURE EP System suggest potential cost savings of approximately $418.10 per procedure. While this suggests that PURE EP might promote shorter procedural times, further studies are underway. "With over 75,000 AF ablations performed in the US each year2 the ability to demonstrate that PURE EP may reduce procedure times resulting in potential healthcare cost savings is a landmark milestone for the overarching value proposition of our technology," said Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc. "We believe a hospital can generate a meaningful return on investment in the first year of ownership of a PURE EP(TM) System. Additional studies demonstrating compelling clinical and economic value of the PURE EP System are in motion and we are looking forward to sharing these insights with the EP and healthcare community in the near future."

08:14 EST Applied Digital announces groundbreaking of HPC facility in North Dakota - Applied Digital announced the groundbreaking of its latest specialized processing center, a five-megawatt facility next to the Company's currently operating 100-MW hosting facility in Jamestown, North Dakota. This separate and unique building, designed and purpose-built for Graphics Processing Units, will sit separate from the Company's current buildings and plans to host more traditional high performance computing, HPC, applications, such as natural language processing, machine learning,and additional HPC developments. "Our greatest asset is our ultra-low-cost-power and the ability to build near the source of power in moreremote locations," said Applied Digital Chairman and CEO, Wes Cummins. "In the past, datacenters were built to support high speed, ultra-low latency communications applications, but these new HPC applications such as machine learning, artificial intelligence and others require a large amount of compute power rather than ultra-low latency communications. Thismeans the digital infrastructure should be built differently and Applied Digital'shomogenous style datacenterscan streamline and significantly lower the cost for running these applications."

08:12 EST Arqit Quantum joins Fortinet Fabric-Ready Partner Program - Arqit announced it has joined the Fortinet Fabric-Ready Partner Program as a Technology Alliance Partner and completed its first integration between Arqit QuantumCloudand Fortinet's FortiGate Next Generation Firewalls.

08:11 EST Kratos Defense receive initial $30M funding on potential $250M C5ISR program - Kratos Defense & Security Solutions announced that it has received the initial $30 million in funding on a potential $250 million Command, Control, Communication, Computing, Combat System Intelligence, Surveillance and Reconnaissance, C5ISR, program. The new contract is single award to Kratos. Work under this new program award will be performed at secure Kratos engineering and manufacturing facilities. Due to competitive, security and other considerations, no additional information will be provided related to this program award. Eric DeMarco, President and CEO of Kratos, said, "Yonah and his team's success on this new, mission critical, National Security related program opportunity is representative of Kratos' successful strategy of providing leading edge disruptive technology products and systems to our customers at an affordable cost. Kratos is positioned for additional expected new program awards in the microwave, hypersonic, satellite communication, propulsion system, drone and other areas."

08:11 EST Verizon announces early access to +play beta - The company said, "Verizon (VZ) announced early access to the +play beta, with one year of Netflix's (NFLX) Premium plan on us when paired with the purchase of select subscription services through +play. +play is a first-of-its-kind content hub exclusive to Verizon mobile and 5G Home and LTE Home customers, designed to help them discover a world of savings and manage their favorite subscriptions from entertainment, news, lifestyle, gaming and more - all in one place, and only on Verizon."

08:08 EST Joby Aviation completes second of four System Reviews required by FAA - Joby Aviation announced the completion of its second of four System Reviews required by the Federal Aviation Administration or FAA as part of the Company's aircraft type certification program. The successful completion of the in-person, multi-day audit by the FAA last week at Joby's facilities in Marina, California, demonstrates the Company's continued leadership on the path to certifying its revolutionary electric vertical take-off and landing, eVTOL aircraft.

08:08 EST Semler Scientific announces publication of study that used QuantaFlo PAD test - Semler Scientific announced that a study was published in the peer-reviewed AJPM Focus with data collected using the company's QuantaFlo PAD test under real-world conditions, illustrating the benefits of PAD in-home screening. AJPM Focus is the official open access journal jointly launched this year by both The American College of Preventive Medicine and the Association for Prevention Teaching and Research. The article is titled "Peripheral Artery Disease Screening in the Community and 1-Year Mortality, Cardiovascular Events, and Adverse Limb Events." The study analyzed screening tests using QuantaFlo for Medicare Advantage beneficiaries aged greater than or equal to65 years participating in the Optum HouseCalls program in the U.S. between April 1, 2017 and February 1, 2019. Of the 192,500 patients tested in their homes, 27.7% had a positive result for PAD. One-year all-cause mortality, 1- and 2-year major adverse cardiovascular events, and major adverse limb events in the PAD positive patients were all significantly increased versus those patients who screened negative for PAD. Moreover, the severity of the test results was associated with worse outcomes.

08:06 EST MKS Instruments presents long-term strategy, financial outlook at Analyst Day - MKS Instruments announced that it will share its long-term strategy and financial outlook at its 2022 Analyst Day. The event is being hosted in Boston and via webcast at 9:00 a.m. Eastern Standard Time. John T.C. Lee, President and CEO Seth H. Bagshaw, Senior Vice President, CFO and Treasurer, and other business leaders will share the Company's vision and strategy to capitalize on strong secular growth opportunities to further expand its position as a foundational enabler of the advanced electronic devices that power our digital world. Presentations will cover key business areas including: Semiconductor, where MKS' critical subsystems touch nearly every key process in chip manufacturing, driving projected continued long-term industry outperformance in the Wafer Fabrication Equipment market; Electronics & Packaging, where MKS' addition of Atotech's proprietary chemistries to its technology portfolio uniquely positions the Company to Optimize the InterconnectSM, where the core building blocks of electronic devices are integrated and connected; and, Specialty Industrial, where MKS leverages its broad domain expertise across vacuum, photonics and chemistry to deliver innovative products and solutions across a wide variety of attractive end markets.

08:04 EST Beam Global receives 'record' orders in 2022 through key government contracts - Beam Global announced that it received record orders in 2022 through key government contracts via extensions to non-contract holders. Beam Global's new and expanded California DGS contract is now available to all 50 states and the federal GSA contract can also be used by a variety of non-federal government agencies. In 2022 contract extension orders totaled over $6.6M, saving local and state governments across the U.S. time and money while enabling them to acquire Beam Global's rapidly deployed EV charging infrastructure products without going through extensive individual contracting processes. The State of California Department of General Services allows government entities in other U.S. states to buy Beam infrastructure products through Beam Global DGS contract #1-22-61-16 at the California negotiated best price, without their having to go through a lengthy competitive procurement or technology review process. Similarly, the federal General Services Administration Multiple Award Schedule Contract Number 47QSWA21D0006, which simplifies the federal procurement process and ensures best pricing, can be used by many state and local government agencies when used for disaster recovery or preparedness purposes. Beam Global EV ARC off-grid EV charging systems qualify as disaster preparedness assets because they continue to charge EVs during grid outages and can be equipped with an emergency power panel. Purchases through these two contract vehicle extensions of Beam products were a record $6.6M in 2022 to date, an increase YOY of over 4000%. Government entities in Arizona, Florida, Maryland, Massachusetts, New Jersey, New Mexico and New York took advantage of these contract vehicles to procure sustainable EV charging infrastructure at best negotiated pricing.

08:04 EST Precision Optics receives $2.6M follow-on production order - Precision Optics announced the receipt of a follow-on production order totaling approximately $2.6M from a major US defense contractor, to meet increased demand for a highly complex optical assembly. The order is expected to be delivered over the next 12 to 18 months. Precision Optics has supplied this optical assembly to the customer since 2018. The new $2.6M order represents a three-fold increase from the most recent order received for this optical assembly. Based on discussions with the customer, the end-market product is seeing increased demand and the customer expects continued ongoing renewals of production orders in the years to come.

08:03 EST Selecta Biosciences announces next generation IgA protease clinical candidate - Selecta Biosciences announced the selection of a next generation Immunoglobulin A, IgA protease from IGAN Biosciences for its IgA nephropathy, IgAN, program. "In preclinical studies, IgA protease has been observed to remove injurious IgA from the kidney and improve markers of renal dysfunction, hallmarks of IgAN," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. "However, development of enzymes derived from common human pathogens have been stifled by immunogenicity that results in the formation of anti-drug antibodies. To address this major hurdle, we worked closely with IGAN Biosciences to identify a new class of IgA protease from a commensal bacteria with a lower level of baseline ADAs. By combining ImmTOR with this next generation IgA protease candidate, we believe our novel approach has the potential to mitigate the formation of new ADAs and address the underlying pathophysiology of the disease. We believe the results observed in clinical trials of our Phase 3 product candidate, SEL-212, provide proof-of-concept for this approach, and we look forward to building on our learnings to expand the potential use of ImmTOR for the treatment of autoimmune diseases."

08:02 EST Microsoft, ViaSat announce new partnership - Microsoft (MSFT) and Viasat (VSAT) announced a new partnership to help deliver internet access to 10M people around the globe, including 5M across Africa. Viasat, a global communications company, is the first satellite partner to work with Microsoft's Airband Initiative, and together they will deepen Airband's work in the Democratic Republic of the Congo, Nigeria, Guatemala, Mexico, and the United States, as well as prioritize expanding the program to Egypt, Senegal and Angola to deliver much-needed internet connection, often for the first time. This first of its kind global partnership for Airband is an important step in reaching the Initiative's expanded goal of delivering internet access to a quarter of a billion people across the world, including 100 million people on the continent of Africa, by the end of 2025.

08:02 EST Infinera receives 'AA' ESG rating from MSCI - Infinera announced that it received an "AA" environmental, social, and governance ratings score in the new 2022 MSCI ESG Ratings. The "AA" rating reinforces Infinera's focus on and commitment to minimizing risks and maximizing opportunities relating to ESG.

07:53 EST Small Pharma to support University College London research on neuroplasticity - Small Pharma announces that it will provide its drug candidate SPL026, an intravenous formulation of the psychedelic drug N, N-dimethyltryptamine, to support a University College London led study investigating induced brain changes and neuroplasticity following intravenous DMT. The Understanding Neuroplasticity Induced by Tryptamines Project is a longitudinal brain-imaging study being conducted by the UCL department of Psychology and Language Science, which seeks to provide a mechanistic understanding of how DMT impacts brain function, behaviour and well-being. The UNITy Project will use Functional Magnetic Resonance Imaging to image the brain before, during and after a DMT or placebo infusion. Follow-ups with study participants will occur for up to nine months.

07:48 EST Signify Health announces expansion of relationship with Ardent Health Services - Signify Health announced an expansion of its relationship with Ardent Health Services, a premier provider of healthcare services with more than 200 sites of care across six states. A former participant in the Center for Medicare and Medicaid Innovation's Bundled Payments for Care Improvement-Advanced BPCI-A program, Ardent will join a 2023 Signify-enabled accountable care organization to implement care transformation, manage risk and provide high-quality, coordinated care for its Medicare patients. Ardent's affiliated network of facilities and physicians in New Mexico, Oklahoma, Texas, and Kansas will work together with independent providers in a collaborative ACO model to achieve the benefits of scale and to effectively manage risk. The strategic collaboration will support alignment with the Centers for Medicare & Medicaid Services' goal of having all Medicare beneficiaries enrolled in an accountable relationship by 2030.

07:42 EST Avicanna, Sante Cannabis initiate study of RHO Phyto CBG transdermal gel - Avicanna announced that it will be initiating an observational real-world evidence study using RHO Phyto branded Cannabigerol transdermal gel on patients with musculoskeletal pain and inflammation together with Sante Cannabis, a clinical research site and contract research organization. The research study will seek to enroll 100 patients and evaluate patient-reported efficacy of the RHO Phyto CBG Transdermal Gel containing 2% Cannabidiol and 1% CBG on arthritis including osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and/or joint pain, localized pain, post-surgical pain, muscular and/or structural injuries. The participants, as identified by the healthcare provider will take part in a 3-month study including clinical visits at baseline and 3-month follow-up assessment. In addition to demographic, medical history, medication use and overall symptom assessment questionnaires, the patients will complete the Musculoskeletal Health Questionnaire, a validated measure of symptoms and quality of life. The study will be conducted by Sante Cannabis, an independent medical cannabis clinic and research services provider. Sante Cannabis has developed a data collection platform and centred model in executing upon its role as a CRS and CRO. The prospective study is expected to launch in early Q1 2023.

07:39 EST Marimed appoints Jon Levine as interim Chief Executive Officer - MariMed announced its Board of Directors appointed Jon Levine, MariMed's President, as Interim Chief Executive Officer. The Board will conduct a process to identify a permanent Chief Executive Officer for MariMed, which may include external and internal candidates. The Company will announce an update on the process upon completion. No timing was provided for the duration of the process.

07:38 EST Revival Gold reports remaining drilling results at Beartrack-Arnett - Revival Gold builds on the Company's 2022 drilling results with the announcement of remaining drill results in the Joss and South Pit target areas at the Beartrack-Arnett Gold Project located in Idaho, USA. Highlights: Four core holes were completed in 2022 in the Joss and South Pit areas over approximately 1.2 kilometers of prospective structure known as the Panther Creek Shear; The first three holes, BT22-241D and BT22-242D at Joss and BT22-243D at South Pit, intersected high-grade gold proximal to the post-mineralization Panther Creek Fault; The fourth core hole, BT22-244D released today, drilled between Joss and the South Pit, intersected 0.58 g/t gold over 6.4 meters1. The hole appears to have penetrated the PCF in the vicinity of an intersecting cross-fault; The mineralization encountered in BT22-244D was intersected on the west side of the PCF and is thought to be associated with South Pit mineralization. Joss mineralization occurs on the east side of the PCF. Only weakly anomalous gold values were encountered east of the PCF in hole BT22-244D. It appears that Joss mineralization has been removed, or displaced, by post-mineral faulting in the vicinity of this hole; Revival Gold's 2022 drilling supports the Company's interpretation that higher-grade mineralization within the mineralized Panther Creek Shear occurs in broad, southerly plunging "shoots". Mineralization is known to extend for at least 5.6 kilometers along strike of the PCF and is open in all directions. Joss extends over a strike of 1,000 meters and has been drilled to a depth of over 500 meters. The twenty core holes that have intersected Joss to-date average 7.7 g/t gold over 5.5 meters drilled width within a broader zone of 2.8 g/t gold over 45.5 meters drilled width1. See Revival Gold press releases dated December 2nd, 2021, September 12th, 2022, and September 22nd, 2022, for details; and, Assay results for the eighteen additional core drill holes completed in 2022 in the Haidee oxide target area are expected in January. Review of all 2022 drill hole data will continue into early 2023. "We've moved the geological model for gold mineralization at Beartrack-Arnett into sharper focus with this year's drilling. Results point to Beartrack-Arnett hosting broad "shoots" of higher-grade mineralization that plunge steeply to the south", said Hugh Agro, President & CEO. "Follow-up drilling will focus on extending the potential width and depth of the shoots at both Joss and the South Pit and on discovering new high-grade shoots elsewhere on the project", Agro added.

07:33 EST MICT's Tingo Mobile establishes strategic presence in Malawi, East Africa - MICT announced that its wholly owned subsidiary, Tingo Mobile Limited, has launched in Malawi, as it establishes a strategic presence in East Africa and accelerates its pan-African rollout. Having already achieved a substantial user base in West Africa, which is expected to expand considerably in the coming months, Tingo Mobile's move into Malawi is an important development for a number of reasons. While Malawi is itself a sizeable target market for Tingo Mobile's Agri-Fintech and FinTech platforms and products, its strategic location is also expected to facilitate accelerated expansion into other key East Africa territories, such as the neighbouring countries of Tanzania, Zambia, and Mozambique. Tingo Mobile's expansion into Malawi and East Africa is expected to facilitate access to significant volumes of the region's key crops, including coffee, tea, cotton, sugar cane, maize, and rice. Darren Mercer, Chief Executive Officer of MICT, commented: "We welcome Malawi into our growing portfolio of geographical markets, as part of our pan-African and global rollout strategy. I could not be more thrilled at the pace of our progress as we continue to internationalize the business and prosper from the benefits we share with Tingo Mobile's customer base. I am particularly proud of our rapidly broadening market reach, and today's expansion into East Africa, as we significantly increase our supply chain and expand the product range for our recently launched commodity platform and export business. When we first considered the acquisition of Tingo Mobile, a key attraction was the international scalability of the business, and the considerable difference we believed we could make to the speed of its rollout and its dollarization. Today's launch into Malawi, within only a few days of launching in Dubai and the Middle East, and only a month since launching in Ghana, is compelling validation of our belief and optimism regarding the huge growth potential of the Group."

07:32 EST First Bank to acquire Malvern Bancorp for $7.80 per share in cash - First Bank (FRBA) and Malvern Bancorp (MLVF) announced that they have entered into a definitive merger agreement pursuant to which First Bank will acquire Malvern Bancorp and Malvern Bank in a transaction valued at approximately $149.5M. The merger has been unanimously approved by the boards of directors of both institutions and is expected to be completed in the second quarter of 2023, subject to the approval of First Bank and Malvern Bancorp, Inc. shareholders, as well as customary regulatory approvals. "This strategic transaction expands our market position and deposit share in eastern Pennsylvania, while complementing our strong organic growth strategy," said Patrick L. Ryan, President and Chief Executive Officer of First Bank. "This merger is another example of what we believe are high-quality and low-risk transactions we are using to build size and scale, solidify our market position and expand our service area. Malvern Bank's emphasis on commercial lending, private banking and superior customer service create a great fit, and we are delighted to welcome Malvern Bank's employees to the First Bank team. In addition, this transaction further strengthens our balance sheet through loan portfolio diversification and provides expanded access to cost-effective deposits. Importantly, we expect the transaction will be significantly and immediately accretive to First Bank earnings per share and that the earn back on tangible book dilution to be under two and a half years. First Bank's regulatory capital levels will remain strong, enabling us to continue to evaluate all appropriate growth opportunities." According to terms of the merger agreement, Malvern Bancorp, Inc. shareholders will receive 0.7733 shares of First Bank common stock and $7.80 in cash per each Malvern Bancorp, Inc. common share outstanding. First Bank expects to issue approximately 5.9 million new shares of First Bank common stock and $59.4 million in cash consideration to consummate this transaction. Based upon First Bank's December 13, 2022 closing price of $15.31 per share, the transaction is valued at approximately $149.5 million in aggregate deal value.

07:26 EST NET Power to become public through Rice Acquisition Corp. II combination - Rice Acquisition Corp. II (RONI) announced a definitive agreement to enter into a business combination to accelerate deployment of NET Power's proprietary technology that delivers clean, reliable, and low-cost power from natural gas. After the business combination, the company will be named NET Power Inc. The transaction is expected to close in the second quarter of 2023 and the combined company will be listed on the NYSE under the ticker symbol (NPWR). Upon closing of the transaction, Ron DeGregorio, current CEO of NET Power will be succeeded by Danny Rice, current director of RAC II and former CEO of Rice Energy, Inc., to lead NET Power through commercialization and beyond. The leadership team and board of directors of the combined company have decades of experience in operations, engineering, management, and investment in energy and power generation. The business combination of RAC II and NET Power at pro forma enterprise value of $1.46B. Assuming no redemptions, the transaction is expected to provide NET Power with approximately $535M of cash net of transaction fees, consisting of $347M of cash in trust of which $10M is subject to a non-redemption agreement, and $225M of PIPE commitments. Total committed investment of $235M is comprised of $100M from the Rice Family and affiliates through a $90M PIPE commitment and $10M non-redemption agreement, and PIPE commitments of $100m from Occidental, $5M from 8 Rivers, $5M from Constellation, and $25M from other investors. Net proceeds of $200M secured through the committed investments are expected to fully fund corporate operations through commercialization of SN1 with expected commissioning in 2026. Net proceeds above $200M are expected to advance and support commercialization, including funding of SN1. Existing NET Power shareholders are rolling 100% of their equity into the combined company and will own approximately 70% of the pro forma equity assuming no redemptions. The business combination, which was recommended to RAC II's board of directors by RAC II's management team, has been unanimously approved by the RAC II board and is expected to close in the second quarter of 2023, subject to certain closing conditions, including receipt of approval by holders of a majority of the shares held by RAC II's shareholders. The business combination was also recommended to NET Power's board of directors by NET Power's management team and has been unanimously approved by the NET Power board.

07:16 EST Nutriband approved for dual listing on Upstream - Nutriband announced its approval to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. Trading begins on Upstream January 5, 2023 at 10:00am ET under the ticker symbol 'NTRB.'

07:14 EST Bannix Acquisition extends deadline to consummate business combination - Bannix Acquisition announced that its sponsor, Bannix Management has extended the deadline by which the Company must complete a business combination by three months, from December 14, 2022 to March 14, 2023. In order to fund the $690,000 deposit required to allow for such extension, the Company has obtained a loan from Instant Fame, LLC evidenced by a non-interest-bearing promissory note that is payable upon the consummation of a business combination by the Company. If the Company fails to consummate a business combination, the outstanding debt under the promissory note will be forgiven, except to the extent of any funds held outside of the Company's trust account after paying all other fees and expenses of the Company.

07:13 EST Telesat, Artel announces signing of Artel's MSA for Telesat Lightspeed - Telesat and Artel announced the signing of Artel's Master Services Agreement, MSA, for Telesat Lightspeed services. The MSA follows a previously signed Memorandum of Understanding, where the companies began a technical and commercial collaboration to integrate secure, low-latency Telesat Lightspeed connectivity into Artel's value-added services portfolio. "Artel is an innovative leader in government connectivity and we're delighted to build on our longstanding partnership," stated Glenn Katz, Telesat's Chief Commercial Officer. "The advanced Telesat Lightspeed architecture, combined with Artel's wide range of value-added services, will provide a compelling value proposition for government customers, with transformative capabilities to ensure mission success."

07:11 EST GXO Logistics teams with BD Rowa to optimize storage, retrieval - GXO Logistics (GXO) announced that it is deploying the BD Rowa Vmax technology solution in partnership with manufacturer BD (BDX), providing value-added services, including a fully automated reverse logistics system, for a major telecommunications provider. "We're excited to partner with BD Rowa to bring its state-of-the-art automation and material-handling capabilities to our customer," said Marv Cunningham, Chief Operations Officer and Chief Information Officer for Americas and Asia Pacific, GXO. "With help from innovative partners like BD Rowa, we'll continue to offer exceptional service for our customers around the globe, reducing costs, improving accuracy and shortening cycle times." By leveraging the high-density storage and retrieval power of BD RowaTM Vmax robots, GXO will be able to deliver high-capacity performance once the full suite of 39 BD RowaTM Vmax robots has been installed. Processing includes the storage and retrieval of mobile phones after they are returned, scanning and tracking them by electronic serial numbers as they move throughout the warehouse.

07:09 EST Kymera Therapeutics announces results from Phase 1 trial of KT-474 - Kymera Therapeutics (KYMR) announced positive clinical results from the patient cohort portion of its KT-474 Phase 1 clinical trial, as well as updates on its three oncology programs: KT-413, KT-333 and KT-253. IRAK4 Degrader: Part C of Kymera's KT-474 Phase 1 clinical trial was designed to confirm that the PK/PD and safety data previously demonstrated in healthy volunteers would translate into patients with hidradenitis suppurativa and atopic dermatitis. Sanofi (SNY), which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, has notified Kymera of its commitment to advance KT-474 into Phase 2 clinical studies. Initial Phase 2 clinical trial of KT-474 will investigate its potential in HS and AD with the first study initiating in 2023. Pharmacokinetics/IRAK4 Pharmacodynamics: In patients with HS and AD, KT-474 demonstrated plasma PK in Part C that was comparable to healthy volunteers in MAD3. Baseline IRAK4 level in skin lesions of HS and AD patients was approximately two-fold higher compared to healthy volunteers. KT-474 demonstrated IRAK4 knockdown in both blood and skin that was comparable to MAD3, with maximum degradation exceeding 90%. Target degradation was similar across HS and AD patients in both blood and skin. Safety: KT-474 was generally safe and well-tolerated, with no serious adverse events, no drug-related infections, and no dose interruptions or discontinuations due to adverse events. Adverse events, which included headache, fatigue and diarrhea, were predominantly mild, and all fully resolved. Oncology Degraders: KT-333, KT-413, KT-253: STAT3 degrader program: The Phase 1a dose escalation portion of the trial is ongoing; dose level 1 has been completed with a total of four patients enrolled. Plasma PK and PD translated as expected in humans with mean maximum STAT3 degradation in PBMC following the first 2 doses averaging 66%, with maximum STAT3 knockdown of up to 86% as measured by mass spectrometry. There were no DLTs or treatment-related SAEs observed in DL1. DL2 [0.10 mg/kg] is currently enrolling. Kymera plans to share additional STAT3 clinical data in 2023. IRAKIMiD degrader program: The Phase 1 clinical trial of KT-413 is designed to evaluate the safety, tolerability, PK/PD and clinical activity of KT-413 administered as an IV infusion once every 3 weeks to adult patients with relapsed and/or refractory B-cell non-Hodgkin's lymphomas. The Phase 1a dose escalation portion of the trial is ongoing; dose level 1 and dose level 2 have been completed. Plasma PK and PD translated as expected in humans with DL1 and DL2 showing dose-dependent degradation of IRAK4, Ikaros and Aiolos in PBMC, with up to 95/100% knockdown of Ikaros/Aiolos and 40% knockdown of IRAK4 in DL2. Serial tumor biopsies at Cycle 3/Day 4 in the patient treated at DL1 showed comparable knockdown of Ikaros/Aiolos and IRAK4 as in plasma. There were no DLTs or treatment-related SAEs and no neutropenia observed in DL1 and DL2 patient cohorts. Kymera plans to share additional IRAKIMiD clinical data in 2023. MDM2 degrader program: Kymera is currently preparing to initiate a Phase 1 clinical trial evaluating the safety, tolerability, PK/PD and clinical activity of KT-253 in adult patients with liquid and solid tumors in 2023. Kymera plans to share more details around the trial design and timelines in early 2023.

07:09 EST Nevro announces presentation of two abstracts for PDN and NSBP - Nevro announced that two abstracts for Painful Diabetic Neuropathy, or PDN, and Non-Surgical Back Pain, or NSBP, were accepted for podium presentations at the 2023 North American Neuromodulation Society Annual Meeting, and will be presented during the late-breaking plenary sessions on January 13-14, 2023 in Las Vegas, NV. A total of 18 abstracts covering Nevro's proprietary 10 kHz Therapy(TM) were accepted for presentation at NANS 2023, including two late-breaking presentations, seven podium presentations and nine posters. Key presentations are highlighted below. Nevro's PDN data presentation will highlight complete 24-month follow-up results for pain relief and improved neurological function. Nevro's SENZA-PDN trial is the largest, Level 1 randomized controlled trial of spinal cord stimulation treatment studying PDN completed thus far with 216 randomized subjects. Results will be presented by Erika A. Petersen, MD, from the University of Arkansas for Medical Sciences, on January 14, 2023, during the E3 Session: Critical Updates in Neuromodulation. A second PDN data presentation will feature the results showing improvement in multiple quality of life metrics with 10 kHz Therapy. Results will also be presented by Erika A. Petersen, on January 13, 2023 during the E1 Session: APP. Nevro's NSBP data presentation will feature 24-month outcomes from its SENZA-NSRBP RCT investigating 10 kHz Therapy for treating non-surgical refractory back pain, with 159 randomized participants from 15 study centers. Results will be presented by Leonardo Kapural, from Carolinas Pain Institute, Winston-Salem, NC, on January 13, 2023, during the Plenary Session II: Late-Breaking Abstracts. A second NSBP data presentation will feature the important improvements in non-pain outcomes such as sleep, mental health and function experienced by patients treated with 10 kHz Therapy in the SENZA-NSRBP RCT. Results will be presented by Jessica Jameson, MD, FASA, from Axis Spine Center, Coeur d'Alene, ID on January 13, 2023, from during the D1 Session: Spine.

07:06 EST Lennox sees growth in revenue, margin and EPS in 2023 - CEO Alok Maskara said, "For 2023, Lennox expects residential unit softness to be overcome by the cumulative impact of price, mix and productivity to deliver growth in revenue, margin and EPS. The cash flow forecast accounts for technology investments and additional commercial manufacturing capacity to deliver on our core value of excellence when serving our customers during the upcoming A2L refrigerant transition." Maskara added, "The forecasted lower annual corporate costs reflect the G&A benefit of consolidating into two operating segments and the planned divestiture of European operations. For 2026, the forecast margin strength is the result of manufacturing productivity initiatives, engineering and sourcing-led cost-reduction efforts to further reduce product costs, and leveraging SG&A while continuing to offset inflation with price. The overall outlook reflects the benefit of our sharp focus on the North American end-market."

07:04 EST Lennox sees FY23 CapEx $250M - For FY23 expects: Corporate expenses of approximately $80 million; Interest expense of $55-$60 million An effective tax rate of 19-21% on an adjusted basis; Capital expenditures of approximately $250 million, including investments in the new Commercial manufacturing facility and investments for the upcoming refrigerant regulatory transition; Cash from operations of $500-$600 million and free cash flow of $250-$350 million; Stock repurchases of $100-$200 million; A weighted average diluted share count of 35-36 million shares.

07:04 EST ObsEva provides update towards meeting Nasdaq stockholder's equity rule - ObsEva (OBSV) announced announced an update on its progress towards meeting Nasdaq's minimum stockholders' equity requirement. As previously announced, on August 19, 2022, the Company received a letter from the Nasdaq Stock Exchange notifying the Company that it is not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Global Select Market. Nasdaq Listing Rule 5450(b)(1)(A) requires listed companies listed on the Nasdaq Global Select Market to maintain stockholders' equity of at least $10M. The Nasdaq Letter was based on the Company's Form 6-K dated August 17, 2022, disclosing financial information for the period ended June 30, 2022, which reported shareholders' equity of negative $2,103,000. ObsEva submitted its plan to regain compliance on August 29, 2022. On November 22, 2022, the Company announced the sale of all its rights to Ebopiprant, an investigational, orally active, selective prostaglandin F2alpha receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions, to XOMA Corporation (XOMA) for an upfront payment of $15M. Additionally, ObsEva is eligible to receive future milestone payments of up to $98M upon the achievement of certain development and regulatory milestones and sales milestones relating to the development of Ebopiprant under a license agreement with Organon. In July 2021, ObsEva granted a license to Organon for the global development, manufacturing, and commercial rights to Ebopiprant. As a result of the Transaction, the stockholders' equity of the Company as of November 30, 2022 is approximately $11.4M. The Company therefore believes that as of the date hereof the Company has regained compliance with Nasdaq Listing Rule 5450(b)(1)(A). Nasdaq will continue to monitor the Company's ongoing compliance with the stockholders' equity requirement and, if at the time of its annual report for the year ended December 31, 2022 the Company does not evidence compliance, it may be subject to delisting. There can be no assurance that the Company will be able to maintain compliance with the minimum stockholders' equity requirement.

07:02 EST Genprex announces SRC approved final cohort in REQORSA Phase 1/2 clinical trial - Genprex announced that the Safety Review Committee, or SRC, has approved continuation to the third and final cohort in the dose escalation Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of in combination with Tagrisso to treat late-stage non-small cell lung cancer, or NSCLC. In 2020, the combination of REQORSA and osimertinib received FDA Fast Track Designation for treatment of the Acclaim-1 patient population. Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial evaluating the Company's lead drug candidate, REQORSA Immunogene Therapy, in combination with Tagrisso (osimertinib) in patients with late-stage NSCLC whose disease progressed after treatment with Tagrisso.

06:57 EST Ur-Energy signs second multi-year uranium sales agreement with fuel company - Ur-Energy announced that it has signed a second multi-year uranium sales agreement with a nuclear fuel company. The new sales agreement calls for the annual delivery of 300,000 pounds of uranium concentrates over a five-year period beginning in 2024. Sales prices are anticipated to be profitable on a company-wide, all-in cost basis and are escalated annually from the initial pricing in 2024. The agreement also provides that a 2029 commitment of 300,000 pounds may be agreed to by the parties no later than year-end 2026. The company's total sales quantity now under contract is 500,000 pounds U3O8 per year beginning in 2024, plus or minus a small flex. The company previously announced its initial multi-year agreement for sales of 200,000 pounds U3O8 annually beginning in 2023. Pursuant to the company's request, that previously announced sales agreement is conditioned on Ur-Energy securing additional contractual commitments to support a development decision. Ur-Energy continues in its ongoing discussions with other nuclear fuel companies with the objective of layering in sufficient additional term offtake contracts to incentivize a ramp-up of production at Lost Creek.

06:47 EST Spire Global to launch six satellites on the SpaceX Transporter-6 mission - Spire Global will launch six satellites on the SpaceX Transporter-6 mission from Cape Canaveral Space Force Station no earlier than January 2023. The satellites will demonstrate advancements and new capabilities for Spire's weather and aviation solutions. Spire will launch two demonstration satellites carrying next-generation Automatic Dependent Surveillance-Broadcast, or ADS-B, payloads, which collect aircraft position data. The satellites will expand Spire's existing ADS-B constellation and play an integral role in improving coverage and latency for the Company's aviation products. They will demonstrate sophisticated technology for global aircraft tracking, including an advanced antenna design based on years of in-orbit ADS-B payload experience and state-of-the-art inter-satellite links. The satellites will be Spire's first to have propulsion systems on board. The multipurpose satellites will also carry payloads to monitor Automatic Identification System signals for vessel tracking data and for Space Services customer Myriota, a provider of global Internet of Things, or IoT, service from satellites.

06:02 EST Tiziana granted additional 180 days by Nasdaq to regain compliance - Tiziana Life Sciences announced that it has received a notification letter from Nasdaq Stock Market that the Company has been granted an additional 180-day compliance period, with a new deadline of June 12, 2023, to regain compliance with Nasdaq's minimum bid price rule. Nasdaq's extension notice has no immediate effect on the continued listing status of the Company's common stock on The Nasdaq Capital Market LLC under the trading symbol, "TLSA." The Company intends to monitor the closing bid price of its common stock between now and June 12, 2023, and has available options within the second compliance period to rectify the deficiency and regain compliance with the minimum bid price requirement. The Company's common stock will continue to be listed and trade on the Nasdaq Capital Market during this period.

05:14 EST Tuniu regains compliance with Nasdaq - Tuniu announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market dated December 13, informing the company that it has regained compliance with the Nasdaq Listing Rule 5450.

05:08 EST Eli Lilly, EVA Pharma enter insulin delivery collaboration - Eli Lilly and EVA Pharma announced a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries, most of which are in Africa. In a first for Lilly, the company will supply its active pharmaceutical ingredient, or API, for insulin at a significantly reduced price to EVA Pharma. Lilly will also provide a pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges - establishing the company as a trusted manufacturer of these lifesaving products in Africa. EVA Pharma expects to begin distribution of the African-made insulin products within 18 months and to reach one million people per year by 2030. This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality healthcare for 30 million people living in limited-resource settings, annually, by 2030.